Literature DB >> 24045770

Position statement on ethics, equipoise and research on charged particle radiation therapy.

Mark Sheehan1, Claire Timlin2, Ken Peach2, Ariella Binik3, Wilson Puthenparampil4, Mark Lodge5, Sean Kehoe6, Michael Brada7, Neil Burnet8, Steve Clarke9, Adrian Crellin10, Michael Dunn1, Piero Fossati11, Steve Harris2, Michael Hocken12, Tony Hope1, Jonathan Ives13, Tadashi Kamada14, Alex John London15, Robert Miller16, Michael Parker1, Madelon Pijls-Johannesma17, Julian Savulescu18, Susan Short19, Loane Skene20, Hirohiko Tsujii14, Jeffrey Tuan11, Charles Weijer3.   

Abstract

The use of charged-particle radiation therapy (CPRT) is an increasingly important development in the treatment of cancer. One of the most pressing controversies about the use of this technology is whether randomised controlled trials are required before this form of treatment can be considered to be the treatment of choice for a wide range of indications. Equipoise is the key ethical concept in determining which research studies are justified. However, there is a good deal of disagreement about how this concept is best understood and applied in the specific case of CPRT. This report is a position statement on these controversies that arises out of a workshop held at Wolfson College, Oxford in August 2011. The workshop brought together international leaders in the relevant fields (radiation oncology, medical physics, radiobiology, research ethics and methodology), including proponents on both sides of the debate, in order to make significant progress on the ethical issues associated with CPRT research. This position statement provides an ethical platform for future research and should enable further work to be done in developing international coordinated programmes of research. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Clinical Trials; Position Statements (of organizations/groups); Radiology; Research Ethics

Mesh:

Year:  2013        PMID: 24045770     DOI: 10.1136/medethics-2012-101290

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  9 in total

1.  Proton beam therapy: the next disruptive innovation in healthcare?

Authors:  Samuel Swisher-McClure; Stephen M Hahn; Justin Bekelman
Journal:  Postgrad Med J       Date:  2015-05       Impact factor: 2.401

2.  Reference pricing with evidence development: a way forward for proton therapy.

Authors:  Justin E Bekelman; Stephen M Hahn
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

Review 3.  Proton beam therapy: perspectives on the National Health Service England clinical service and research programme.

Authors:  Neil G Burnet; Ranald I Mackay; Ed Smith; Amy L Chadwick; Gillian A Whitfield; David J Thomson; Matthew Lowe; Norman F Kirkby; Adrian M Crellin; Karen J Kirkby
Journal:  Br J Radiol       Date:  2020-01-14       Impact factor: 3.039

4.  Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study.

Authors:  Alessandro Ruggi; Fraia Melchionda; Iacopo Sardi; Rossana Pavone; Linda Meneghello; Lidija Kitanovski; Lorna Zadravec Zaletel; Paolo Farace; Mino Zucchelli; Mirko Scagnet; Francesco Toni; Roberto Righetto; Marco Cianchetti; Arcangelo Prete; Daniela Greto; Silvia Cammelli; Alessio Giuseppe Morganti; Barbara Rombi
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

5.  Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?

Authors:  S Patel; X Kostaras; M Parliament; I A Olivotto; R Nordal; K Aronyk; N Hagen
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

Review 6.  Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances.

Authors:  Nikhil T Sebastian; Meng Xu-Welliver; Terence M Williams
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 7.  Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus.

Authors:  Paulo Zielinsky; Stefano Busato
Journal:  Birth Defects Res C Embryo Today       Date:  2013-12

8.  Protocol for a systematic scoping review of reasons given to justify the performance of randomised controlled trials.

Authors:  Brian Dewar; Mark Fedyk; Lucas Jurkovic; Stephanie Chevrier; Rosendo Rodriguez; Simon C Kitto; Raphael Saginur; Michel Shamy
Journal:  BMJ Open       Date:  2019-07-26       Impact factor: 2.692

9.  Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.

Authors:  Justin E Bekelman; Hien Lu; Stephanie Pugh; Kaysee Baker; Christine D Berg; Amy Barrington de González; Lior Z Braunstein; Walter Bosch; Cynthia Chauhan; Susan Ellenberg; L Christine Fang; Gary M Freedman; Elizabeth A Hahn; B G Haffty; Atif J Khan; Rachel B Jimenez; Christy Kesslering; Bonnie Ky; Choonsik Lee; Hsiao-Ming Lu; Mark V Mishra; C Daniel Mullins; Robert W Mutter; Suneel Nagda; Mark Pankuch; Simon N Powell; Fred W Prior; Karen Schupak; Alphonse G Taghian; J Ben Wilkinson; Shannon M MacDonald; Oren Cahlon
Journal:  BMJ Open       Date:  2019-10-15       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.